• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Gelatin, Soft Capsule Gelatin, Hard Capsule Gelatin, Pharmaceutical Gelatin-Foodmate
Neohesperidin
Advantame
Cleanroom Bench Horizontal Laminar Flow Hood Airflow Clean Bench
Pharma and Food Grade, USP/FCC Neotame Sweetener E961
Trilobatin

Dr. Reddy's Laboratories Announces the Launch of Venlafaxine ER Tablets in the U.S. Market

AmericanPharmaceuticalReviewDecember 13, 2021

Tag: Venlafaxine , USFDA , Dr. Reddy

Dr. Reddy’s Laboratories Ltd. announced the launch of Venlafaxine ER Tablets which is therapeutically equivalent to Venlafaxine Extended-Release Tablets, 150 mg and 225 mg, of Osmotica Pharmaceutical US LLC approved by the U.S. Food and Drug Administration (USFDA).

The brand and generic had U.S. sales of approximately $51 million MAT for the most recent twelve months ending in October 2021 according to IQVIA Health*.

Dr. Reddy’s Venlafaxine ER Tablets are available in 150 mg and 225 mg strengths in bottle count sizes of 30 and 90.

Previous:EMA recommends RoActemra in adults with severe COVID-19

Next:Lilly and Regor sign deal to develop treatments for metabolic disorders

Related News

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Everest Medicines LimitedDecember 20, 2024

Everest Medicines announced NMPA acceptance of NDA for VELSIPITY(R) (etrasimod) to treat moderately to severely active UC.

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

PRNewswireDecember 12, 2024

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

PRNewswireDecember 12, 2024

Dr. Reddy's Laboratories Announces the Launch of Venlafaxine ER Tablets in the U.S. Market | Pharmasources.com

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

PRNewswireDecember 12, 2024

Core8 Group, an Australian leader in high-tech and biotech innovation, has unveiled plans to develop Vietnam's first AI x ESG Hospital, marking a significant milestone in healthcare transformation.

You may like
More>>

venlafaxine hydrochloride

venlafaxine hydrochloride
Venlafaxine HCl

Venlafaxine HCl
Venlafaxine

Venlafaxine
Desvenlafaxine succinate

Desvenlafaxine succinate
Desvenlafaxine succinate

Desvenlafaxine succinate
Venlafaxine HCL

Venlafaxine HCL
Factory Supply Venlafaxine CAS 93413-69-5

Factory Supply Venlafaxine CAS 93413-69-5
Venlafaxine

Venlafaxine
Venlafaxine hcl

Venlafaxine hcl
Venlafaxine Hydrochloride

Venlafaxine Hydrochloride

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service